26 of 88 ( 30 % ) target lesion revascularisations in the zotarolimus-eluting stent group occurred between 1 and 5 years ' follow-up , whereas 54 of 70 ( 77 % ) of those in the sirolimus-eluting stent group occurred during this follow-up period .